Irinotecan and bevacizumab in recurrent glioblastoma multiforme
- 9 March 2011
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Pharmacotherapy
- Vol. 12 (5) , 825-833
Abstract
(2011). Irinotecan and bevacizumab in recurrent glioblastoma multiforme. Expert Opinion on Pharmacotherapy: Vol. 12, No. 5, pp. 825-833. doi: 10.1517/14656566.2011.566558Keywords
This publication has 76 references indexed in Scilit:
- Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and miceNeuro-Oncology, 2010
- Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomideNeuro-Oncology, 2009
- Safety and Efficacy of Bevacizumab With Hypofractionated Stereotactic Irradiation for Recurrent Malignant GliomasInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2009
- Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastomaJournal of Neuro-Oncology, 2009
- Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant MetastasisCancer Cell, 2009
- Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant GliomasClinical Cancer Research, 2008
- Modes of resistance to anti-angiogenic therapyNature Reviews Cancer, 2008
- Bevacizumab/Irinotecan. Un nouveau traitement actif dans les gliomes de haut grade récidivants : résultats préliminaires d’une étude multicentrique de l’AnocefRevue Neurologique, 2008
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapseBritish Journal of Cancer, 2000